Department of Medical Biotechnology, University of Siena, via Aldo Moro 2, 53100 Siena, Italy.
Zambon S.p.a, Via della Chimica, 9. 36100 Vicenza, Italy.
Molecules. 2019 Nov 25;24(23):4290. doi: 10.3390/molecules24234290.
The synthetic antimicrobial peptide SET-M33 is being developed as a possible new antibacterial candidate for the treatment of multi-drug resistant bacteria. SET-M33 is a branched peptide featuring higher resistance and bioavailability than its linear analogues. SET-M33 shows antimicrobial activity against different species of multi-resistant Gram-negative bacteria, including clinically isolated strains of , , and . The secondary structure of this 40 amino acid peptide was investigated by NMR to fully characterize the product in the framework of preclinical studies. The possible presence of helixes or β-sheets in the structure had to be explored to predict the behavior of the branched peptide in solution, with a view to designing a formulation for parenteral administration. Since the final formulation of SET-M33 will be strictly defined in terms of counter-ions and additives, we also report the studies on a new salt form, SET-M33 chloride, that retains its activity against Gram-negative bacteria and gains in solubility, with a possible improvement in the pharmacokinetic profile. The opportunity of using a chloride counter-ion is very convenient from a process development point of view and did not increase the toxicity of the antimicrobial drug.
合成抗菌肽 SET-M33 正被开发为一种治疗多重耐药菌的新型候选抗菌药物。SET-M33 是一种分支肽,比其线性类似物具有更高的耐药性和生物利用度。SET-M33 对不同种类的多重耐药革兰氏阴性菌具有抗菌活性,包括临床分离株 、 、 和 。通过 NMR 研究了这种 40 个氨基酸肽的二级结构,以在临床前研究的框架内充分表征产物。必须探索结构中是否存在螺旋或β-折叠,以预测分支肽在溶液中的行为,以期设计用于肠胃外给药的制剂。由于 SET-M33 的最终制剂将严格根据抗衡离子和添加剂来定义,我们还报告了关于新型盐形式 SET-M33 氯化物的研究,该盐形式保留了对革兰氏阴性菌的活性并提高了溶解度,可能改善了药代动力学特征。从工艺开发的角度来看,使用氯化物抗衡离子的机会非常方便,并且不会增加抗菌药物的毒性。